Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy.
Toni K ChoueiriCamillo PortaCristina SuárezJohn HainsworthEric VoogIgnacio DuranJames ReevesPiotr CzaykowskiDaniel CastellanoJingjing ChenFarhad SedaratiThomas PowlesPublished in: The oncologist (2022)
Sapanisertib with or without TAK-117 was less tolerable and did not improve efficacy vs. everolimus in patients with advanced ccRCC who had relapsed after or were refractory to VEGF-targeted therapies. Dual mTORC1/2 inhibition may not be an effective therapeutic approach for these patients.
Keyphrases
- end stage renal disease
- renal cell carcinoma
- open label
- vascular endothelial growth factor
- endothelial cells
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute myeloid leukemia
- acute lymphoblastic leukemia
- placebo controlled
- peritoneal dialysis
- randomized controlled trial
- phase iii
- clinical trial
- phase ii